Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Stock Information for Rezolute Inc.
Loading
Please wait while we load your information from QuoteMedia.